Johnson & Johnson

A U.S. appeals court has dismissed the bankruptcy case filed by a Johnson & Johnson spinoff company. Around 40,000 cancer patients have filed suit, alleging the powder was contaminated with asbestos.

Critics say a legal maneuver by one of the world's wealthiest corporations could set a precedent, allowing non-bankrupt companies and rich individuals to avoid liability for wrongdoing.

Drug manufacturers invested in Russia’s pharmaceutical industry contend international humanitarian law requires they continue manufacturing and selling their products there, even while condemning the Ukraine invasion.

The companies, including Johnson & Johnson and McKesson, will admit no wrongdoing. Billions of dollars in payouts will fund drug treatment and harm reduction programs.

Two studies that have not yet been peer reviewed indicate increased protection against the infectious omicron variant.

The agency implemented experts' advice because of a rare and sometimes fatal blood-clotting problem known as TTS. More than 16 million people in the U.S. have received a shot of the J&J vaccine.

The pharmaceutical and medical device business will keep the J&J name while the division that sells Band-Aids and Listerine will go it alone.

CDC Director Rochelle Walensky also endorsed a mix-and-match approach to boosters that would be flexible for patients and health care providers.

The Food and Drug Administration also gave an OK to boosters that differ from the vaccine originally used to immunize people against COVID-19. A mix-and-match approach could ease the booster rollout.

A panel of experts voted to recommend that the Food and Drug Administration authorize a booster dose of the Johnson & Johnson COVID vaccine at least two months after the first shot.